BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steve Aselage purchased 2,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was purchased at an average price of $8.30 per share, for a total transaction of $16,600.00. Following the transaction, the director now directly owns 2,000 shares in the company, valued at approximately $16,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of NASDAQ:BCRX traded down $0.13 during mid-day trading on Friday, hitting $8.06. The company had a trading volume of 2,044,168 shares, compared to its average volume of 759,843. The firm has a market capitalization of $883.71 million, a P/E ratio of -8.22 and a beta of 1.81. The company has a quick ratio of 1.98, a current ratio of 2.00 and a debt-to-equity ratio of 0.43. BioCryst Pharmaceuticals, Inc. has a one year low of $4.53 and a one year high of $9.95.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $2.73 million during the quarter, compared to analyst estimates of $2.39 million. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 167.73%. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.
BCRX has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 23rd. Royal Bank of Canada boosted their price target on shares of BioCryst Pharmaceuticals to $16.00 and gave the stock a “positive” rating in a research report on Tuesday, December 4th. Finally, Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $12.18.
Several large investors have recently added to or reduced their stakes in BCRX. Paloma Partners Management Co bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $84,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $122,000. Amalgamated Bank bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $122,000. Legal & General Group Plc increased its stake in shares of BioCryst Pharmaceuticals by 14.5% in the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 2,453 shares in the last quarter. Finally, Ibex Investors LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $216,000. Institutional investors own 92.34% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Steve Aselage Purchases 2,000 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock” was originally published by Equities Focus and is the sole property of of Equities Focus. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.equitiesfocus.com/2019/03/17/steve-aselage-purchases-2000-shares-of-biocryst-pharmaceuticals-inc-bcrx-stock.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: What is Depreciation?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.